VolitionRx Secures €2 Million Funding to Enhance Diagnostic Solutions and Market Accessibility

VolitionRx Secures New Funding to Advance Innovative Diagnostic Solutions

VolitionRx Limited, a multinational epigenetics company, announces the successful raise of €2.0 million (approximately $2.3 million) to bolster the development of its Nu.Q® product portfolio. This financing, provided by Namur Invest and Wallonie Entreprendre S.A. in Belgium, is earmarked for supporting the regulatory transition of Nu.Q® NETs from IVDD (In Vitro Diagnostic Directive) to IVDR (In Vitro Diagnostic Regulation). This transition is essential for VolitionRx, as it aligns with their strategic objective of enhancing the commercialization of their diagnostic products across different markets, particularly in low-income regions. The funding will also assist in developing a Lateral Flow product, which is aimed at making the Nu.Q® NETs accessible to a broader demographic.

Prominent figures from both supporting organizations have expressed their enthusiasm about working with VolitionRx. Mr. Nicolas Delahaye from Namur Invest highlights the company's innovative drive in epigenetics, which positions them at the forefront of revolutionizing disease detection. Additionally, Mr. Géry Lefebvre of Wallonie Entreprendre S.A. emphasizes the significance of supporting companies that possess robust technological platforms like Volition, which can lead to tangible advancements in healthcare. The financial backing reflects confidence in Volition's mission to innovate within the diagnostics field, which is critical in increasing the accessibility of vital medical tests.

Dr. Gaetan Michel, the Chief Operating Officer of Volition, emphasizes the impact of this recent financing in reinforcing the company's strategy for securing non-dilutive funding. With total non-dilutive funding exceeding $25 million, the additional funds mark a pivotal step forward in the company’s plans. The current financing includes various timelines for disbursement based on achieving specified milestones, demonstrating the strategic approach VolitionRx takes to advance its research and commercialization objectives. As the company progresses through the year, it aims to reach significant milestones that attest to the advancements made in its product offerings and overall mission of enhancing early detection and monitoring capabilities in healthcare.

In addition to this funding announcement, VolitionRx is steadfast in its commitment to operational excellence and innovation in the detection of life-altering diseases. The company intends to leverage the new capital to further refine its technologies and expand its market presence. By facilitating easier access to effective diagnostic tools, particularly in underserved areas, VolitionRx aims to contribute significantly to global health improvements through early disease detection.

The regulatory and product development processes propelled by this funding underscore VolitionRx's essential role in reshaping the landscape of diagnostic medicine and improving outcomes for patients around the world.